Table of Contents Table of Contents
Previous Page  76 / 812 Next Page
Information
Show Menu
Previous Page 76 / 812 Next Page
Page Background European Psychiatry 33S (2016) S72–S115

Available online at

ScienceDirect

www.sciencedirect.com

24th European Congress of Psychiatry

Free communications

Addictive behaviours

FC01

“Dual disorder with drugs”:

Comparison of two French databases

A. Batisse

1 ,

, N. Taright

2

, C. Chevallier

1

, M. Marillier

1

,

S. Djezzar

1

1

Groupe hospitalier Lariboisière/Fernand-Widal/Saint-Louis,

CEIP-Addictovigilance, Paris, France

2

AP–HP, Département d’information médicale, Paris, France

Corresponding author.

Context

Dual diagnosis (substance used disorders (SUD) and

mental illness) represents 3% of general population. Among United

States population, 42.3% of SUD patients have psychiatric troubles

(without tobacco). Moreover, SUD can concern all psychoactive

substances (PAS) or illicit PAS only named “dual disorder with

drugs” (DDD).

Methods

A quantitative analysis of DDD data from January 2013

to July 2014 of two epidemiological tools has been performed:

PMSI database (Programme Médicalisé des Systeme d’Information)

hospital discharge data is made up of data providing medical infor-

mation for all patients discharged in Paris public hospital system

(AP–HP) and NOT’S is a vigilance database of spontaneous NOTifi-

cations of drug abuse and dependence. We propose a descriptive

analysis of DDD in Paris metropolitan area.

Results

With PMSI, 9.2% of SUD inpatients (

n

= 617) have DDD,

with mean age of 46 years (62% of men). In comparison, NOT’S

reports 36% of SUD with DDD (

n

= 302) with mean age of 39.5 years

(68% of men). Suicide attempt is also listed and reach 23% of cases.

Conclusion

These two databases

( Table 1 )

show the difficulty of

DDD diagnosis with the discordance in results. DDD miss in PMSI

database since addictovigilance database shows a first prevalence

of DDD. Despite the high rates of DDD, the problem is often under

diagnosed by clinicians practising. It is also important to promote

the collaboration among health care workers (addictologist and

psychiatrist) because these patients require intensive mental and

substance abuse care.

Table 1

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.005

FC02

25I-NBOMe: The legal LSD

I. Ezquiaga

1 ,

, M. Grifell

2

, L. Galindo

2

, L. Martínez

1

,

Á. Palma

2

, P. Quintana

3

, M. Ventura

4

, E. Ribera

1

, L. Pujol

1

,

I. Fornís

4

, M. Torrens

2

, M. Farré

5

1

Institut de Neuropsiquiatria i Addiccions, Parc de Salut Mar,

Psychiatry, Barcelona, Spain

2

Institut de Neuropsiquiatria i Addiccions, Parc de Salut Mar, IMIM,

Universitat Autònoma de Barcelona, Psychiatry, Barcelona, Spain

3

Energy Control, Asociación Bienestar y Desarrollo, Energy Control,

Primary Care, Barcelona, Spain

4

Energy Control, Asociación Bienestar y Desarrollo, Energy Control,

Barcelona, Spain

5

Hospital Universitari Germans Trías i Pujol, IGTP, Universitat

Autònoma de Barcelona, Psychiatry, Barcelona, Spain

Corresponding author.

Introduction

Novel psychoactive substances (NPS) use is progres-

sively increasing year on year. A new group of phenethylamines

sold as legal stimulants and hallucinogens is being reported

increasingly since 2012. Within this group, 25I-NBOMe is an out-

standing substance with powerful effects and high affinity with

the serotonin 2a (5HT2a) receptor. Several toxicity cases have been

reported so far.

Objectives

To describe the presence of 25I-NBOMe and its charac-

teristics in samples delivered to Energy Control from 2009 to 2015

in Spain.

0924-9338/$ – see front matter